Case Study 4: False Positives in AI-Powered Software as a Medical Device (SaMD)

A digital health startup launched an AI-driven SaMD designed to predict chronic conditions using data from wearable devices. Shortly after release, users began receiving alarming false-positive alerts for serious conditions, even when stable.

These false alerts created public concern, triggered unnecessary clinical evaluations, and strained customer trust. The startup faced reputational damage and paused its product rollout.

The company initiated an internal investigation into the root cause and subsequently engaged Compliance Insight to provide regulatory perspective and guidance. While the technical work was handled by the internal data science team, we offered strategic advice on validation planning, documentation, and regulatory expectations.

After revalidation and improved oversight, the product was reintroduced successfully to the market.

Key Takeaway: Clinical AI systems must undergo rigorous validation. Compliance Insight can provide regulatory perspective and support to ensure readiness for FDA expectations.

Compliance Insight, Inc.
497 Circle Freeway Dr., Suite 230
Cincinnati, Ohio 45246
www.compliance-insight.com